A condition, known commonly as "black urine disease" or Alkaptonuria is a rare genetic disorder involving protein metabolism, and it has its root in the mutation of the homogentisate 1,2-dioxygenase gene, which in turn causes homogentisic acid accumulation in the body. The appearance of dark urine after exposure to air is due to this kind of accumulation; however, a variety of symptoms can be expected, such as joint stiffness, changes in pigmentation, and other long-term health complications. Although the prevalence has been estimated to be between 1 in 250,000 and 1 in 1 million people in the United States, its effects are indeed high on those affected.

Alkaptonuria is an autosomal recessive disease, meaning that the child must inherit a defective copy of the HGD gene from both parents. If both parents are carriers, their offspring have a 25% chance of inheriting two faulty genes and developing alkaptonuria. The condition is genetic but is often not diagnosed for years because it progresses slowly and its early symptoms appear to be harmless.

Symptoms of Alkaptonuria

The most characteristic and common initial symptom of alkaptonuria is dark urine. The reason for this is due to the fact that excess HGA is excreted in the urine and upon oxidation in the presence of air, it gives the urine a brown or black color. Though it is often considered cosmetic, the long-term accumulation of HGA within the connective tissues produces more complicated health problems.

Progressive joint pain and stiffness: The accumulation of HGA in cartilage leads to early-onset osteoarthritis, making movement increasingly difficult over time.

Skin and eye pigmentation changes: Affected individuals may develop bluish or grayish discoloration of the sclera (white part of the eye) and the skin, particularly in areas exposed to friction.

Cardiovascular and respiratory problems: With age, HGA accumulation can lead to valve calcifications in the heart and stiffening of connective tissues in the respiratory tract, which can cause problems in middle and old age.

Decreased mobility and spinal problems: The spine may become stiff and painful due to chronic cartilage degeneration.

These symptoms usually begin to manifest during adulthood, leading to severe complications in a person's 40s or 50s and significantly affecting the quality of their life.

How is Alkaptonuria Diagnosed?

Because of its rarity, alkaptonuria is often mistaken or overlooked early in life. However, there are several ways to confirm the condition:

Urine Testing: The gold standard in the diagnosis is the testing of urine samples for high levels of homogentisic acid via gas chromatography. In case of oxidation, which changes the color of urine to black, it is indicative of alkaptonuria.

Genetic Testing: Confirmatory genetic testing reveals mutations of the HGD gene to diagnose the condition conclusively.

Blood Tests: High levels of HGA in the blood can be used as further evidence.

Imaging Studies: X-rays and MRIs will expose cartilage and joint damage characteristic of alkaptonuria.

Management of Alkaptonuria: Is There A Cure?

At present, there is no cure for alkaptonuria; however, various treatment approaches can reduce its symptoms and slow the disease's progress:

Nitisinone Therapy: Nitisinone is a drug that inhibits the production of HGA. It has been shown to reduce HGA levels and slow tissue damage. However, it needs to be taken under close medical supervision because of potential side effects.

Low-Protein Diet: Since HGA is a byproduct of protein metabolism, reducing protein intake—especially foods rich in tyrosine and phenylalanine—may help decrease HGA production.

Pain Management: OTC pain relievers and anti-inflammatory medications can be used to relieve joint pain and stiffness.

Physical Therapy: Exercise regularly, as it may improve mobility and strengthen muscles, thus reducing strain on affected joints.

Surgical Interventions: Most people with alkaptonuria develop severe osteoarthritis necessitating joint replacement in their old age. Also, some may require heart valve replacement surgery if cardiovascular complications develop.

Life with Alkaptonuria

Although alkaptonuria is not fatal, it severely affects the quality of life. The progressive deterioration of the joints and associated symptoms can make everyday activities difficult, requiring lifestyle changes and medical interventions. The disease may cause premature aging of the joints, requiring walking aids and mobility assistance earlier than expected.

Ongoing research will continue to work on improving the treatment options by focusing on gene therapy and alternative enzyme replacement therapies. However, because of its rarity, the clinical trials and research remain sparse.

As genetic research advances, more hope for better management and possible curative approaches for alkaptonuria exists. Scientists are searching extensively for enzyme replacement therapies and innovative drugs that can target the root cause of the disorder. Being aware and being diagnosed early helps individuals better their condition and ultimately have better long-term health outcomes.

Alkaptonuria is a striking example of how one gene mutation can have widespread effects on the body. Though still a rare and often misunderstood condition, growing awareness and advances in treatment are paving the way for better care. If you or a loved one suspect symptoms of alkaptonuria, it is essential to seek early diagnosis and medical guidance to manage the disease effectively and preserve quality of life.

In today's busy routines, acidity is a common complaint — almost one in five people take an acidity tablet. Most of us don't think twice before reaching for one.

A little heartburn after dinner, some burning in the chest, a feeling of heaviness - one pantoprazole tablet and the problem seems solved. And for many people, it quietly becomes a habit that they continue taking for weeks and sometimes even months.

Why This Matters for Cancer Patients

In limited doses and under medical guidance, an acidity tablet is largely considered safe. But this is not true for everyone. For patients undergoing immunotherapy for kidney cancer, that small tablet may be doing more than just controlling acidity.

A patient comes in for follow-up. The scans look encouraging. Treatment is going as planned. And then, almost casually, they mention that they have been taking pantoprazole every morning for acidity for several years without proper medical advice. Most patients genuinely don't think it's important enough to mention. But newer research suggests it might be.

The Gut Microbiome Connection

It is because the digestive system holds trillions of bacteria collectively called the gut microbiome. Once thought to help only with digestion, they are now known to be deeply connected to the immune system.

Our gut bacteria are a training ground for our immune army. If that ecosystem is disturbed, the immune response may not be as effective as we want it to be.

This is where these proton pump inhibitor medicines, such as pantoprazole, omeprazole, and rabeprazole, can also alter the balance of gut bacteria by suppressing acid production in the stomach. This seemingly minor change may have a stronger effect.

What Does Research Show

A study published in the Journal of Cancer Research and Clinical Oncology looked at patients with advanced kidney cancer receiving immunotherapy, comparing those who regularly used PPIs with those who did not.

The difference surprised many oncologists. Patients who were not taking daily PPIs had a progression-free survival of around 9.7 months, and for regular PPI users, it was around 6.4 months. When overall survival was measured, the gap was even wider — about 14.6 months for daily PPI users compared with roughly 30 months for non-users.

And this is not a one-off finding. When researchers pooled fourteen studies covering 6,716 cancer patients on immunotherapy, PPI users still carried roughly a 39 percent higher relative risk of death and a 29 percent higher risk of the cancer progressing. A larger 343-patient kidney cancer study echoed the very same direction. Although not every analysis agrees on how big the effect is — some of the most recent data suggest it may be more modest — but the arrow keeps pointing the same way.

An Important Caveat

One important caveat runs through all of it: these are observational studies, not controlled trials. PPI users are often older and have more illnesses, which can independently worsen outcomes, so the pill cannot yet be said to cause the difference.

A finding this consistent cannot simply be ignored. It deserves to be part of the discussion before treatment starts. He added that PPIs are also recognized, quite separately, as an occasional cause of kidney injury — one more reason their use is worth reviewing rather than continuing on autopilot.

Don't Stop Your Medication Suddenly

At the same time, stopping acidity medicines overnight is not the solution. When patients suddenly stop PPIs, they can experience severe rebound acidity. That's why any change should happen only after discussing it with the treating doctor.

Simple Steps Patients Can Take

A practical piece of advice would be to carry a complete list of medicines to every oncology appointment — not just cancer medicines, but everything.

Prescription drugs, over-the-counter tablets, supplements, and even home remedies. Sometimes alternatives are available. Sometimes simple dietary changes help — smaller meals, less spicy food, avoiding late-night eating. Simple measures, but often effective.

Remember, cancer treatment is not only about the drug. It is also about everything happening around the drug. The food people eat. The medicines they take. Their daily habits. Small things can sometimes influence big outcomes.

(Dr Veenoo Agarwal, Head of Medical Oncology at Shalby International Hospital, Gurugram)

Even though Sickle Cell Disease (SCD) affects thousands of families across the country, it continues to remain one of India's most under-recognized health challenges.

The National Sickle Cell Elimination Mission, launched in 2023, has brought renewed focus to the disease, with the goal of reducing the incidence of new sickle cell disease cases to zero by 2047.

The mission has largely focused on prevention and supportive care, but a comprehensive 360-degree approach is still missing, Dr. Gaurav Kharya, Clinical Lead, Centre for Bone Marrow Transplant & Cellular Therapy, Senior Consultant, Pediatric Hematology, Oncology and Immunology, Indraprastha Apollo Hospitals, New Delhi, told HealthandMe.

“The current framework does not adequately address patients who continue to suffer from severe sickle cell disease despite receiving optimal supportive care,” Dr. Gaurav said.

“Such patients may be candidates for curative approaches such as bone marrow transplantation and, in the future, gene therapy. At present, bone marrow transplantation remains the available curative option,” he added.

Dr. Gaurav noted that for decades, treatment focused primarily on controlling symptoms and managing complications. The mission led to free genetic screening cards, lifestyle counseling, and access to symptom-managing medication.

"While these measures remain important, advances in stem cell and bone marrow transplantation have changed the treatment landscape for selected patients”.

The Sickle Cell Mission does not currently address transplant support or provide specific directives to state governments regarding curative treatment.

“The impact of these interventions can be life-changing. Children who once depended on repeated hospital visits, blood transfusions and constant medical care may be able to look forward to healthier and more independent lives after successful treatment,” Dr Gaurav said.

The expert called for “incorporating support for curative therapies and allocating dedicated funding could strengthen the program and create a truly comprehensive approach that focuses equally on prevention, supportive care and curative treatment”.

Achievements of Sickle Cell Mission

Also read: Your Kidneys Could Be Silently At Risk From Work Stress And Unhealthy Habits, Experts Warn

India contributes a significant proportion of global sickle cell births every year, making it a major public health concern.

The disease is particularly prevalent in several regions of India, especially among tribal and underserved populations in states such as Madhya Pradesh, Maharashtra, Chhattisgarh, Gujarat, Odisha and Rajasthan.

One of the major achievements of the Sickle Cell Elimination mission has been bringing attention to a disease that had long remained neglected. Previously, policy-making, implementation, and fund allocation for sickle cell disease in high-burden states were limited.

The mission has brought a strong focus on sickle cell disease, prompting states with a high disease burden, including Madhya Pradesh, Chhattisgarh, Odisha, Gujarat and Maharashtra, to actively work on policy-making and implementation.

The primary objective of the mission has been prevention. Dr. Gaurav told HealthandMe that prevention can only happen when individuals know their sickle cell status and whether they carry the gene responsible for the disease.

“Once identified, individuals can receive counselling on how the disease can be prevented. Proper genetic counselling can help families understand the risks associated with passing the condition to future generations,” he said.

Following the implementation of the mission, large-scale screening programs have been conducted, particularly in high-burden states. These efforts have led to the identification of significant numbers of people with sickle cell trait as well as individuals with homozygous sickle cell disease.

Another key objective of the mission is to provide optimal supportive care to patients. Many patients have been linked to nearby Primary Health Centers (PHCs) and Community Health Centers (CHCs) to ensure access to regular medicines and supportive treatments such as hydroxyurea. Associated genetic counselling has also been initiated as part of these efforts.

To help reduce the number of children born with severe disease, Dr Gaurav urged for further boosting

• awareness of carrier status,
• access to genetic counseling
• wider implementation of screening programs.

What Is Sickle Cell Disease?

Sickle Cell Disease is an inherited blood disorder that affects the shape and function of red blood cells. Instead of being round and flexible, the red blood cells become sickle or crescent-shaped, making it difficult for them to move smoothly through blood vessels.

This can lead to severe anemia, recurrent episodes of pain, infections, organ damage and, in some cases, life-threatening complications such as stroke or acute chest syndrome.

The impact of Sickle Cell Disease extends far beyond physical symptoms, Dr Gaurav said. Children living with the condition often experience repeated hospital visits, missed school days and limitations in daily activities.

Parents frequently face emotional distress, financial strain and the challenge of managing a lifelong medical condition.

Why Early Diagnosis Matters

Dr Gaurav said that one of the biggest challenges is that many children are diagnosed only after symptoms begin to appear. Early screening can help identify affected infants before serious complications develop, allowing doctors to initiate preventive care and monitor the disease more effectively.

Newborn screening programs, regular follow-ups, and access to specialized care can significantly improve the quality of life and reduce the risk of long-term complications, the expert told HealthandMe.

“Sir, this insurance company has a claim settlement ratio of more than 98%. It’s damn safe! Go with this health insurance policy…”

Most people hear such assurances from their friends or insurance agents and sigh with relief before they plan to buy a health insurance plan. But wait! Is knowing the claim settlement ratio sufficient?

A common notion about health insurance companies is, “The higher the CSR, the more reliable the insurance company. The lower its CSR, the less will be its trustworthiness.” However, this is an incomplete rationale.

The CSR alone can’t tell you everything about a health insurer's credibility; you need to dive deeper into many other key aspects.

This article will make you aware of why judging the worthiness of a health insurance plan based on an insurer’s claim settlement ratio can be a blunder.

What Does The CSR Tell About The Health Insurance Policy?

The Claim Settlement Ratio (CSR) of a health insurance company primarily indicates the percentage of claims an insurer settles.

Here is the formula to calculate the CSR:

CSR = (Total Claims Settled/ Total Claims Received ) × 100

A common belief is that higher CSR signals a more reliable company, while lower CSR indicates less trustworthiness.

However, this is not a universal truth. Several other factors determine an insurer's reliability.

4 Ways Your Health Insurer’s CSR Might Mislead You!

While the Claim Settlement Ratio (CSR) indicates the percentage of claims an insurer settles, relying on it solely can be misleading because it fails to capture critical aspects of the customer experience, service quality, and financial stability.

Here’s how CSR conceals vital facts about a health insurance company, misleading the policyholders:

1. Hides turnaround time (TAT)

The CSR does not reveal how long it takes for a claim to be processed and paid. A high CSR could belong to an insurer that takes months to settle claims, leading to significant financial stress for the policyholder during a medical emergency.

2. Ignores the quality of settlement

The CSR only measures whether a claim was settled or rejected, not the amount that was paid out. A claim might be approved, but if a large portion is partially denied due to sub-limits or exclusions, the policyholder still faces high out-of-pocket costs. Policyholders now demand a comprehensive breakdown and rationale for every claim decision, especially partial denials.

3. Doesn’t reflect claim-transparency

A high CSR doesn't guarantee a good claims journey. Policyholders now want to know the real-time claim status, just like an ‘Uber cab-style’ tracking of their claim status. They expect clear communication and transparency in hospital billing at negotiated rates. Opaque processing, even with a high final settlement, erodes trust.

4. Claims served, and claims settled.

Very often, health insurance companies highlight the number of claims processed in a year as a major milestone. An ordinary buyer is led into the illusion of a prestigious business journey by the insurance company and finalizes enrolment in its health insurance plan. Wait for a while to know the concept!

Total served annually is the number of claims the health insurer receives in a year, much like daily footfall at a popular store or mall. It doesn’t tell you how many claims were actually settled out of it.

So, next time you look for a health insurance policy, don’t get disillusioned with the flowery language and heroic claims of claims settlement. Ask the insurance agent for every detail mentioned above about the insurance policy.

What Are The Parameters Of A Reliable Insurer, Apart From CSR?

Insurers and experts advise focusing on a combination of metrics for a complete assessment of an insurer's performance:

1. Incurred Claim Ratio (ICR)

Unlike CSR, which tracks claim volume, ICR offers a financial view by comparing total claim payouts to premiums collected. A healthy ICR proves insurers aren't overcharging or risking solvency, fostering long-term trust in their financial stability. An ideal ICR ranges from 50% to 80% shows that the insurer is using a fair share of premiums to pay claims, reflecting financial stability and a commitment to policyholders.

2. TAT for cashless claim settlement

In accordance with IRDAI regulations, health insurers are required to adhere to specific turnaround times for claim settlements, after all necessary documentation has been submitted:

● 1 hour for cashless pre-authorization,

● 3 hours for processing cashless discharge requests, and

● 15 days for the settlement of reimbursement claims.

3. Grievance redressal speed

Customer loyalty largely depends on how quickly the insurer resolves disputes. Top-tier health insurance companies aim to resolve 95% of complaints within 3 working days.

These are some of the crucial parameters that decide the credibility of a health insurance policy. You must verify these aspects to ensure the safety of your premiums invested.

How Are Health Insurers Making Their Plans More Reliable?

Leading health insurers are now making their plans more reliable by shifting focus beyond the CSR to redefine customer care, by focusing on achieving the following aspects:

● Proactive and personalized engagement: Using predictive analytics for anticipatory support, offering dedicated health concierges for complex issues, and tailoring support based on the member's life stage.

● Seamless digital integration for self-service: They are achieving this by integrating all interactions into a single digital platform (app/web portal), and ensuring transparent, paperless, real-time claim tracking.

● Incentivizing wellness: Actively promoting incentivized wellness programs, implementing systematic post-hospitalisation follow-up to reduce readmissions, and using data to initiate proactive, preventive care interventions.

● Empathy and human-centric design: Employing highly trained, empathetic agents for quick issue resolution, and using continuous feedback mechanisms like Customer Satisfaction (CSAT) and Net Promoter Score (NPS) to improve procedures.

With the above strategies, health Insurers are transforming from just policy payers to wellness partners for policyholders’ healthcare journeys.

Wrapping Up

When choosing a health insurance policy, relying solely on the CSR is an incomplete and potentially misleading approach. A truly reliable insurer must be judged on a combination of financial and service metrics.

Today, the excellence of health insurance providers is measured by their ability to offer proactive support.

This includes providing seamless digital self-service options, promoting wellness through incentivized programs, and managing every interaction with genuine empathy and human-centric design.